TXG Relative Valuation
TXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TXG is overvalued; if below, it's undervalued.
Historical Valuation
10X Genomics Inc (TXG) is now in the Fair zone, suggesting that its current forward PS ratio of 2.13 is considered Fairly compared with the five-year average of -105.32. The fair price of 10X Genomics Inc (TXG) is between 12.92 to 177.34 according to relative valuation methord.
Relative Value
Fair Zone
12.92-177.34
Current Price：18.15
Fair
-8.62
PE
1Y
3Y
5Y
Trailing
Forward
-7.40
EV/EBITDA
10X Genomics Inc. (TXG) has a current EV/EBITDA of -7.40. The 5-year average EV/EBITDA is -559.48. The thresholds are as follows: Strongly Undervalued below -4214.47, Undervalued between -4214.47 and -2386.98, Fairly Valued between 1268.01 and -2386.98, Overvalued between 1268.01 and 3095.50, and Strongly Overvalued above 3095.50. The current Forward EV/EBITDA of -7.40 falls within the Historic Trend Line -Fairly Valued range.
-5.90
EV/EBIT
10X Genomics Inc. (TXG) has a current EV/EBIT of -5.90. The 5-year average EV/EBIT is -106.33. The thresholds are as follows: Strongly Undervalued below -407.99, Undervalued between -407.99 and -257.16, Fairly Valued between 44.50 and -257.16, Overvalued between 44.50 and 195.33, and Strongly Overvalued above 195.33. The current Forward EV/EBIT of -5.90 falls within the Historic Trend Line -Fairly Valued range.
2.13
PS
10X Genomics Inc. (TXG) has a current PS of 2.13. The 5-year average PS is 13.64. The thresholds are as follows: Strongly Undervalued below -10.46, Undervalued between -10.46 and 1.59, Fairly Valued between 25.70 and 1.59, Overvalued between 25.70 and 37.75, and Strongly Overvalued above 37.75. The current Forward PS of 2.13 falls within the Historic Trend Line -Fairly Valued range.
-225.89
P/OCF
10X Genomics Inc. (TXG) has a current P/OCF of -225.89. The 5-year average P/OCF is 84.84. The thresholds are as follows: Strongly Undervalued below -2234.02, Undervalued between -2234.02 and -1074.59, Fairly Valued between 1244.26 and -1074.59, Overvalued between 1244.26 and 2403.69, and Strongly Overvalued above 2403.69. The current Forward P/OCF of -225.89 falls within the Historic Trend Line -Fairly Valued range.
-7.81
P/FCF
10X Genomics Inc. (TXG) has a current P/FCF of -7.81. The 5-year average P/FCF is -60.00. The thresholds are as follows: Strongly Undervalued below -194.88, Undervalued between -194.88 and -127.44, Fairly Valued between 7.44 and -127.44, Overvalued between 7.44 and 74.88, and Strongly Overvalued above 74.88. The current Forward P/FCF of -7.81 falls within the Historic Trend Line -Fairly Valued range.
10X Genomics Inc (TXG) has a current Price-to-Book (P/B) ratio of 1.76. Compared to its 3-year average P/B ratio of 5.11 , the current P/B ratio is approximately -65.59% higher. Relative to its 5-year average P/B ratio of 10.11, the current P/B ratio is about -82.62% higher. 10X Genomics Inc (TXG) has a Forward Free Cash Flow (FCF) yield of approximately 3.65%. Compared to its 3-year average FCF yield of -1.25%, the current FCF yield is approximately -391.29% lower. Relative to its 5-year average FCF yield of -1.62% , the current FCF yield is about -325.31% lower.
1.76
P/B
Median3y
5.11
Median5y
10.11
3.65
FCF Yield
Median3y
-1.25
Median5y
-1.62
Competitors Valuation Multiple
The average P/S ratio for TXG's competitors is 1.06, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TXG increased by 26.39% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -4.74 to -7.79.
The secondary factor is the Revenue Growth, contributed 9.84%to the performance.
Overall, the performance of TXG in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is 10X Genomics Inc (TXG) currently overvalued or undervalued?
What is 10X Genomics Inc (TXG) fair value?
How does TXG's valuation metrics compare to the industry average?
What is the current P/B ratio for 10X Genomics Inc (TXG) as of Dec 05 2025?
What is the current FCF Yield for 10X Genomics Inc (TXG) as of Dec 05 2025?
What is the current Forward P/E ratio for 10X Genomics Inc (TXG) as of Dec 05 2025?